BIELLO, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 2.744
AS - Asia 46
SA - Sud America 8
NA - Nord America 3
Totale 2.801
Nazione #
IT - Italia 2.744
CN - Cina 28
BR - Brasile 8
SG - Singapore 8
VN - Vietnam 7
US - Stati Uniti d'America 3
ID - Indonesia 2
KG - Kirghizistan 1
Totale 2.801
Città #
Genoa 1.091
Genova 1.000
Rapallo 386
Vado Ligure 261
Beijing 10
Bordighera 6
Ho Chi Minh City 4
Singapore 4
Ashburn 3
São Paulo 2
Bishkek 1
Cuiabá 1
Jakarta 1
Juiz de Fora 1
Macapá 1
Montes Claros 1
Ninh Bình 1
Passa Quatro 1
Phủ Lý 1
Santiago 1
Totale 2.777
Nome #
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 153
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 151
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 151
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 143
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 142
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 122
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 115
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 111
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 111
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 110
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 106
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 99
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 99
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 97
Afatinib for the treatment of non-small cell lung cancer 97
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 97
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 95
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 90
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 88
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 86
Vinflunine for the treatment of non-small cell lung cancer 85
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 76
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 75
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review) 74
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 73
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 60
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer 60
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 57
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 55
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 36
Totale 2.914
Categoria #
all - tutte 13.247
article - articoli 13.247
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.494


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021229 0 0 0 0 40 21 11 33 42 37 26 19
2021/2022296 16 8 10 18 14 23 6 63 36 34 15 53
2022/2023431 27 36 8 39 75 68 0 43 65 5 61 4
2023/2024281 7 24 11 36 20 66 14 25 11 26 5 36
2024/2025716 38 43 21 57 80 72 60 163 25 39 65 53
2025/2026389 176 24 79 98 12 0 0 0 0 0 0 0
Totale 2.914